POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA

Their core work

Kuopio University Hospital (KUH) is a major Finnish university hospital that combines clinical care with translational research, particularly in cardiovascular medicine and gene therapy. They run clinical trials testing regenerative therapies for heart disease, contribute clinical expertise and patient cohorts to multi-country health research consortia, and are building capabilities in AI-driven sleep diagnostics. Their strength lies in bridging laboratory research with real patient outcomes in a hospital setting.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), KUH worked across diverse clinical areas — eHealth for urinary incontinence, cancer care methodology, and began their cardiovascular gene therapy programme with ReGenHeart. From 2018 onward, their focus sharpened decisively around cardiovascular research (gene therapy, data sharing, omics) and expanded into digital health through AI-driven sleep diagnostics. The shift from broad clinical participation to deep cardiovascular specialisation plus emerging digital diagnostics marks a clear strategic evolution.

KUH is converging on two growth areas — advanced gene therapies for heart disease and AI-powered diagnostic tools — making them a strong future partner for projects combining clinical data with computational methods.

How they like to work

KUH operates primarily as a clinical partner within large European consortia, having participated in 6 projects versus coordinating just 1 (ReGenHeart, their largest grant at EUR 1.48M). With 129 unique partners across 27 countries, they maintain a very broad network rather than repeating partnerships, suggesting they are sought after for their clinical expertise and patient access. Their willingness to coordinate when the topic aligns with their core strength (cardiovascular gene therapy) shows selective leadership capacity.

KUH has collaborated with 129 unique partners across 27 countries, giving them one of the wider European networks for a hospital of this size. Their partnerships span from EU-Canada joint infrastructure (euCanSHare) to pan-European clinical networks, reflecting strong international connectivity in health research.

What sets them apart

KUH brings the rare combination of a fully operational university hospital environment with deep specialisation in cardiovascular gene therapy — they can take a therapy from laboratory research through clinical trials under one roof. Their coordination of ReGenHeart demonstrates they can lead complex multi-partner clinical development programmes, not just contribute patient data. For consortium builders, they offer validated clinical trial infrastructure in Finland with an established track record in regenerative cardiovascular medicine.

Highlights from their portfolio

• ReGenHeart
  Their only coordinated project and largest grant (EUR 1.48M) — a proof-of-principle clinical trial for regenerative VEGF-D gene therapy for angina, representing their flagship research.
• CardioReGenix
  Next-generation cardiovascular gene therapy using ncRNA, showing continued deepening of their core competence with significant funding (EUR 678K).
• SLEEP REVOLUTION
  Marks a strategic expansion into AI and digital diagnostics for sleep medicine, combining machine learning with personalized healthcare — a new direction for the hospital.